Determining whether Abeona Therapeutics (NASDAQ: ABEO) is a sound purchase depends on your risk tolerance regarding clinical-stage biotechnology equities. Analysts tracking the firm highlight its innovative gene therapy pipeline and regulatory milestones, which give it substantial upside potential. However, early-stage biotech investments carry inherent clinical and commercialization risks, requiring investors to evaluate balance sheet burn rates and personal financial strategies before investing.